ArticleBMC infectious diseases2012
Campylobacter antimicrobial resistance in Peru: a ten-year observational study.
Article in BMC infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 88 citations in OpenAlex.
- Enhancing surveillance of foodborne bacteria and antimicrobial resistance using a large centralized laboratory database: Case study of Campylobacter and nontyphoidal Salmonella in Peru.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026Article
- Phenotypic Resistance of Ciprofloxacin and Azithromycin ResistantbioRxiv : the preprint server for biology · 2026Article
- Raw Milk as a Source ofPathogens (Basel, Switzerland) · 2025Article
- Determination of antibiotic resistance using three phenotypic methods in Campylobacter coli strains isolated from commercial chicken meat in Lima, Peru.Revista peruana de medicina experimental y salud publica · 2025Article
- Open letter: challenging the removal of key bacteria from the updated 2024 WHO Bacterial Priority Pathogen List.Microbial genomics · 2025Article
- In Vitro Therapeutic Efficacy of Furazolidone for Antimicrobial Susceptibility Testing onAntibiotics (Basel, Switzerland) · 2025Article
- The Impact of Antibiotic Resistance in Childhood Campylobacter Infections Before and After the COVID-19 Pandemic in the Southeast Region of Romania.Antibiotics (Basel, Switzerland) · 2025Article
- Genomic resistant determinants of multidrug-resistant Campylobacter spp. isolates in Peru.Journal of global antimicrobial resistance · 2024Article
- Antibiotic Resistance inAntibiotics (Basel, Switzerland) · 2023Review
- Antimicrobial resistance of enteric pathogens in the Military Health System, 2009 - 2019.BMC public health · 2022Article
- Travel-related gastrointestinal diseases: Assessment and management.Public health challenges · 2022Review
- Occurrence of Campylobacter spp. and Phenotypic Antimicrobial Resistance Profiles of Campylobacter jejuni in Slaughtered Broiler Chickens in North-Western RomaniaAntibiotics (Basel, Switzerland) · 2022Article
- Pan-Genome Analysis of Campylobacter: Insights on the Genomic Diversity and Virulence Profile.Microbiology spectrum · 2022Article
- Emerging patterns of fluoroquinolone resistance inMicrobial genomics · 2022Article
- Structure-based inhibitor design for reshaping bacterial morphology.Communications biology · 2022Article
- Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru.BMC research notes · 2021Article
- Occurrence and multidrug resistance of Campylobacter spp. at duck farms and associated environmental and anthropogenic risk factors in Bangladesh.BMC infectious diseases · 2021Article
- Detection of Campylobacter jejuni and Salmonella typhimurium in chicken using PCR for virulence factor hipO and invA genes (Saudi Arabia).Bioscience reports · 2021Article
- Whole Resistome Analysis inFrontiers in microbiology · 2021Article
- Validation of the T86I mutation in the gyrA gene as a highly reliable real time PCR target to detect Fluoroquinolone-resistant Campylobacter jejuni.BMC infectious diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCampylobacter jejuni and Campylobacter coli are food-borne pathogens of great importance and feature prominently in the etiology of developing world enteritis and travellers' diarrhoea. Increasing antimicrobial resistant Campylobacter prevalence has been described globally, yet data from Peru is limited. Our objective was to describe the prevalence trends of fluoroquinolone and macrolide-resistant C. jejuni and C. coli stool isolates from three regions in Peru over a ten-year period.
methodsSurveillance for enteric pathogens was conducted in Lima, Iquitos and Cusco between 2001 and 2010. Campylobacter stool isolates were tested for susceptibilities to ciprofloxacin, azithromycin and erythromycin. Susceptibilities were reviewed for 4652 isolates from Lima ( n = 3419), Iquitos ( n = 625) and Cusco ( n = 608).
resultsComparing the study periods of 2001-2005 and 2006-2010, prevalence of ciprofloxacin-resistant C. jejuni isolates rose in the study areas of Lima (73.1% to 89.8%, p < 0.001) and Iquitos (24.1% to 48.9%, p < 0.001). Ciprofloxacin-resistant C. coli rates also increased in Lima (48.1% to 87.4%, p < 0.001) and Cusco (10.0% to 65.9%, p = 0.005). Small but significant increases in azithromycin-resistant and erythromycin-resistant C. jejuni prevalence were noted in Iquitos (2.2% to 14.9%, p < 0.001; 3.2% to 14.9%, p = 0.002), and erythromycin-resistant C. coli rates increased in Lima (0.0% to 5.3%, p = 0.038). The prevalence of C. jejuni isolates resistant to both ciprofloxacin and azithromycin increased in Iquitos (0.3% to 14.9%, p < 0.001) and Lima (0.3% to 1.6%, p = 0.011), and prevalence of C. jejuni isolates resistant to both ciprofloxacin and erythromycin rose in Iquitos (0.0% to 14.9%, p < 0.001). Ciprofloxacin and erythromycin resistant C. coli prevalence increased in Lima (0.0% to 5.3%, p = 0.034).
conclusionsThese results have implications for the empirical management of enterocolitis in Peru. Ongoing surveillance is essential to guide appropriate antimicrobial use in this setting. Local epidemiological studies to explore the relationship between increasing antimicrobial resistance and agricultural or human antibiotic use may be valuable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.